Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Ciprofibrate 100mg Tablets

Active Ingredient:
ciprofibrate
Company:  
ADVANZ Pharma See contact details
ATC code: 
C10AB08
{info_black}
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 10 Jan 2024
1. Name of the medicinal product

Ciprofibrate 100mg Tablets

2. Qualitative and quantitative composition

Each tablet contains 100mg ciprofibrate as the active ingredient.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Tablet

White to Off White capsule shaped tablet plain on one side and break line on other side.

The break line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

4. Clinical particulars
4.1 Therapeutic indications

Ciprofibrate tablets are indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.

- Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.

4.2 Posology and method of administration

Posology

Adults:

The recommended dosage is one tablet (100mg ciprofibrate) per day. This dose should not be exceeded (see Precautions).

Elderly:

As for adults, but see Precautions and Warnings.

Renal impairment:

In moderate renal impairment (creatinine clearance 30-80 ml/min/1.73m2) it is recommended that dosage be reduced to one tablet every other day. Patients should be carefully monitored. Ciprofibrate should not be used in severe renal impairment (creatinine clearance <30 ml/min/1.73m2).

Paediatric population

Not recommended since safety and efficacy in children has not been established.

Method of administration

For oral use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section6.1.

Severe hepatic impairment.

Severe renal impairment (creatinine clearance <30 ml/min/1.73m2).

Pregnancy and lactation, or when pregnancy is suspected.

Concurrent use with another fibrate.

Previous phototoxicity caused by fibrates

4.4 Special warnings and precautions for use

Myalgia/myopathy:

Patients should be advised to report unexplained muscle pain, tenderness or weakness immediately.

CPK levels should be assessed immediately in patients reporting these symptoms. Therapy should be discontinued if myopathy is diagnosed or if markedly elevated CPK levels (levels exceeding 5 times the normal range) occur.

Doses of 200mg ciprofibrate per day or greater have been associated with a high risk of rhabdomyolysis. Therefore the daily dose should not exceed 100mg.

The risk of myopathy may be increased in the presence of the following predisposing factors:

• impaired renal function and any situation of hypoalbuminaemia such as nephrotic syndrome

• hypothyroidism or untreated hypothyroidism

• alcohol abuse

• age > 70 years

• personal or family history of hereditary muscular disorders

• previous history of muscular toxicity with another fibrate

As with other fibrates, the risk of rhabdomyolysis and myoglobinuria may be increased if ciprofibrate is used in combination with other fibrates or HMG CoA reductase inhibitors (see sections 4.3 and 4.5).

Use with caution in patients with impaired hepatic function.

Periodic hepatic function tests are recommended (every 3 months for the first 12 months of treatment). Ciprofibrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.

Secondary causes of dyslipidaemia, such as hypothyroidism, should be excluded or corrected prior to commencing any lipid lowering drug treatment.

In patients with hypertriglyceridaemia, ciprofibrate may cause an increase of the LDL level

Special precautions for use

Association with oral anticoagulant therapy: concomitant oral anticoagulant therapy should be given at reduced dosage and adjusted according to INR (see section 4.5).

If after a period of administration lasting several months, a satisfactory reduction in serum lipid concentrations has not been obtained, additional or different therapeutic measures must be considered.

Patients with rare hereditary problems of galactose intolerance, the total lactose deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Other fibrates: As with other fibrates, the risk of rhabdomyolysis and myoglobinuria may be increased if ciprofibrate is used in combination with other fibrates (see sections 4.3 and 4.4.).

Not recommended combinations

HMG CoA reductase inhibitors: As with other fibrates, the risk of myopathy, rhabdomyolysis and myoglobinuria may be increased if ciprofibrate is used in combination with HMG CoA reductase inhibitors (see section 4.4). The benefits of combined use should be carefully weighed against the risks. Physicians contemplating concomitant therapy with HMG CoA reductase inhibitors should consult the SPC of the relevant HMG CoA reductase inhibitor as some higher doses are contraindicated / not recommended with fibrates.

Combination requiring caution

Oral anticoagulant therapy: Ciprofibrate is highly protein bound and therefore likely to displace other drugs from plasma protein binding sites. This may increase the effects of drugs like phenytoin, tolbutamide and other sulphonylurea derivatives and coumarin-like anticoagulants. Ciprofibrate has been shown to potentiate the effect of warfarin, indicating that concomitant oral anticoagulant therapy should be given at reduced dosage and adjusted according to INR (see section 4.4).

Combination to be taken into account

Cholestyramine and colestipol may reduce the absorption of ciprofibrate. These drugs should not be taken together or close to each other.

No clinically relevant interactions exist with cytochrome P450, beta blocking agents, calcium antagonists, diuretics, other hypertensives digoxin and nitroglycerin

Oral hypoglycaemics: Although ciprofibrate may potentiate the effect of oral hypoglycaemics, available data do not suggest that such an interaction may be clinically significant.

Oestrogens: Oestrogens can raise lipid levels. Although a pharmacodynamic interaction may be suggested, no clinical data are currently available.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are insufficient data from the use of ciprofibrate in pregnant women. Animal studies have demonstrated neonatal thrombosis (see section 5.3). The potential risk for humans is unknown. Ciprofibrate is contraindicated during pregnancy (see section 4.3)

Breast-feeding

Ciprofibrate is contraindicated during breast-feeding (see section 4.3). It is not known if ciprofibrate is excreted into breast milk.

Fertility

There are no data on the effects of ciprofibrate on fertility in humans.

4.7 Effects on ability to drive and use machines

Dizziness, somnolence, and fatigue have only rarely been reported in association with ciprofibrate. Patients should be warned that if they are affected they should not drive or operate machinery.

4.8 Undesirable effects

The following undesirable effects may occur with the use of Ciprofibrate in the following frequencies:

Rare (≥1/10,000 to <1/1,000);

Very rare (<1/10,000)

Not known (cannot be estimated from the available data).

The following effects have been reported and are listed below by System organ class:

System organ class

Frequency

Undesirable effects

Blood and lymphatic system disorders

Not known

Leukocytopenia

Thrombocytopenia

Nervous system disorders

Rare

Not known

Dizziness

Somnolence

Headache

Vertigo

Respiratory, thoracic and mediastinal disorders

Not known

Pneumonitis or pulmonary fibrosis (Isolated cases)

Gastrointestinal disorders

Not known

Nausea2

Vomiting2

Diarrhoea2

Dyspepsia2

Abdominal pain2

Hepatobiliary disorders

Very rare

Not known

Cholestasis or cytolysis3

Cholelithiasis3

Skin and subcutaneous tissue disorders

Very rare

Not known

Photosensitivity

Rashes, urticaria, pruritus and eczema (mainly allergic)

Alopecia

Musculoskeletal and connective tissue disorders

Rare

Not known

Rhabdomyolysis1

Myalgia1 and myopathy1 including myositis1

Reproductive system and breast disorders

Not known

Erectile dysfunction

General disorders and administration site conditions

Rare

Fatigue

Investigations

Not known

Blood creatine phosphokinase increased

Liver function test abnormal3

1In the majority of cases muscle toxicity is reversible when treatment is withdrawn (see section 4.4).

2Generally, these side effects were mild to moderate in nature and occurred early on, becoming less frequent as treatment progressed.

3As with other fibrates, abnormal hepatic function tests have been observed occasionally. Very rare cases of cholestasis or cytolysis have been reported (see section 4.4). Exceptional cases with chronic evolution have been observed. Some cases of cholelithiasis have been reported.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms

Overdosage with ciprofibrate has been rarely reported. Some cases of overdose are known, but in these cases, no adverse reactions specific to overdose have been observed. In the worst case, after ingestion of 2800 mg ciprofibrate for 3 days, rhabdomyolysis observed.

Treatment

There are no specific antidotes to ciprofibrate. Treatment of overdosage should be symptomatic. The usual measures should be taken to prevent further absorption of the drug from the gastro-intestinal tract. Gastric lavage and appropriate supportive care may be instituted if necessary. Ciprofibrate is non-dialysable.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Serum lipid reducing agents – fibrates, ATC Code: C10A B08

Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol. The mechanism of action of ciprofibrate is not entirely clear. It includes increased VLDL catabolism, but may also be influenced by reduced synthesis of VLDL or direct effect on the LDL receptor

Ciprofibrate is effective in the treatment of hyperlipidaemia associated with high plasma concentrations of LDL and VLDL (types IIa, IIb, III and IV according to the Fredrickson Classification). In clinical studies ciprofibrate has been shown to be effective in complementing the dietary treatment of such conditions.

There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease.

5.2 Pharmacokinetic properties

Absorption and Distribution

Ciprofibrate is readily absorbed in man, with maximum plasma concentrations occurring mainly between one and four hours following an oral dose. Following a single dose of 100mg, in volunteers, maximum plasma concentration of ciprofibrate was between 21 and 36μg/ml. In patients on chronic therapy, maximum levels from 53 to 165μg/ml have been measured. The plasma protein binding of ciprofibrate is about 98% in the therapeutic range.

Elimination

Terminal elimination half-life in patients on long term therapy varies from 38 to 86 hours. The elimination half-life in subjects with moderate renal insufficiency was slightly increased compared with normal subjects (116.7h compared with 81.1h). In subjects with severe renal impairment, a significant increase was noted (171.9h).

Approximately 30-75% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20-25% of the total excreted) or as a conjugate. Subjects with moderate renal impairment excreted on average 7.0% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%.

5.3 Preclinical safety data

In animal studies with respect to reproduction neonatal thrombosis is seen in rats at doses similar to the therapeutic dosage. The potential risk for humans is unknown.

Other findings add nothing to the clinical experience.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose Monohydrate

Hydroxypropyl methyl cellulose

Sodium Lauril Sulphate

Purified water

Microcrystalline cellulose

Maize Starch

Powdered Vegetable Stearing/Hydrogenated vegetable oil

6.2 Incompatibilities

Not applicable

6.3 Shelf life

PVC/Aluminium Blister pack: 3 Years

Aluminium/Aluminium Blister pack: 3 Years

6.4 Special precautions for storage

Do not store above 25°C. Store in the original package to protect from moisture.

6.5 Nature and contents of container

Tablets are packed in clear/transparent PVC/Aluminium or

Aluminium/Aluminium blisters containing 28 Tablets.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Focus Pharmaceuticals Limited

Dashwood House,

69 Old Broad Street,

London, EC2M 1QS,

United Kingdom

8. Marketing authorisation number(s)

PL 20046/0298

9. Date of first authorisation/renewal of the authorisation

05/04/2013

10. Date of revision of the text

03/01/2024

ADVANZ Pharma
Company image
Address
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
Telephone
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 588 9273